FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2021
Commission File Number: 001-36187
CONTENTS
On September 8, 2022, Evogene Ltd. (the “Company”) convened its Annual General Meeting of Shareholders (the “Annual Meeting”), however, it was
adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company’s Annual Meeting will be reconvened on Tuesday, September 15, 2022 at 3:00 p.m. (Israel time), at the executive offices of the Company, 13 Gad
Feinstein Street, Park Rehovot, Rehovot, Israel.
This Form 6-K is incorporated by reference into the registration statements on Form F-3 (Securities and Exchange
Commission (“SEC”) File No. 333-253300), and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of Evogene, and will be a
part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.